PT-141

PT-141, known by its chemical name bremelanotide, is a lab-made peptide that switches on a family of brain receptors called melanocortin receptors rather than acting on blood vessels the way older sexual-function medicines do. A version of it is FDA-approved for a specific diagnosed condition in women, and researchers separately study the same receptor pathway in men and in broader brain-signaling research.

What it is

PT-141 works on two related receptors in the brain and spinal cord, called MC3R and MC4R, part of a signaling system called the melanocortin system that the body also uses to regulate appetite and energy use. Rather than widening blood vessels, the way many sexual-function drugs work, it is described as acting on brain circuits tied to arousal directly.

Because its target sits in the central nervous system rather than in blood vessels, researchers describe PT-141 as working through a different route than drugs like sildenafil, meaning it has been studied in people who did not respond to those more common medicines.

How it is studied

The clinical evidence for PT-141 comes from randomized, placebo-controlled human trials, meaning some participants received the real peptide and others a placebo with no active drug, without either group knowing which they received. Separate laboratory studies used receptor-binding assays in cells and animals to confirm which receptors the peptide activates.

What studies report

In Phase 3 trials in premenopausal women with a diagnosed low-desire condition, PT-141 produced a statistically significant improvement in sexual desire and reduced related distress, with about 24.5 percent of the treatment group showing meaningful improvement compared with about 17.2 percent on placebo. [1]
In clinical studies in men with erectile difficulty, including men who had not responded to standard oral medicines, PT-141 produced erections through central nervous system pathways in a way that scaled with the amount given, meaning larger amounts produced a stronger response. [2]
Laboratory and animal studies confirmed that PT-141 selectively binds the MC3R and MC4R receptors and activates nerve pathways tied to sexual arousal without widening blood vessels in the body. [3]

What is not known

Most of the placebo-controlled clinical trial evidence for PT-141 comes from women with one specific diagnosed condition, and the male erectile-difficulty studies cited here used smaller or differently designed trials, so direct comparison of effect size between men and women is limited. Long-term safety data beyond the trials supporting its approval is not covered in the sources reviewed for this entry.

Reported adverse findings

The FDA-approved product's labeling includes a boxed warning about temporary drops in blood pressure and a related increase in heart rate, and its trials tracked nausea and flushing as common side effects. [1]

Regulatory status

PT-141, marketed as Vyleesi, is FDA-approved specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder, a diagnosed medical condition, and carries a boxed warning about blood pressure effects. It is not approved for use in men, and any use of the underlying peptide outside that approved product and its labeled use is not covered by that approval.